Bullish; also, $1.20 seems very possible, but I prefer to imagine a range of possibilites from 80 cents through to 1.50 in 2024.
As others at HC here have warned, there could/would be the need for yet another capital raise sic before we get a final read of results. Let's hope by that time, if it happens, even a 20% CR decline will be well above today's $0.72 cents. Guesses Q2, Q3, Q4 this year for CR, if there is going to be one in 2024?
Is OPT Sozinibercept an all-or-nothing situation?
What do others think the future may hold if the results are not what we hope for? For example, if the Stage III trials achieve a positive but not statistically significant result for Sozinibercept—hypothetically, "The preliminary findings from the clinical trial indicate potential positive effects; however, the results have not achieved statistical significance to meet FDA standards for conclusive evidence of efficacy"—is OPT a 0 cent stock, or could there be some options?
Personally, I would greatly increase my holding if zero were not a very real possibility. Happy (but not happy) to take a 50% loss eg 30cents , but going to zero would be nasty and thus mitigates the buy button finger.
- Forums
- ASX - By Stock
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
OPT
opthea limited
Add to My Watchlist
0.00%
!
60.0¢

Bullish; also, $1.20 seems very possible, but I prefer to...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
OPT (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online